

OXIS International to Hold Business Update Conference Call on March 22

BEVERLY HILLS, Calif., March 10, 2011 -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) today announced that it will hold a conference call with investors on Tuesday, March 22, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific).

During the call Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will review significant business developments, discuss the Company's growth strategy, and take questions from call attendees.

Individuals interested in listening to the conference call may do so by dialing 866-625-0328 for domestic callers, or 706-643-2088 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.oxis.com.

A 48-hour telephone replay will be available approximately one hour after the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 50932341. The webcast will be available on the Company's Web site for 14 days following the completion of the call.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets.

SOURCE OXIS International, Inc.

CONTACT: Don Markley, Lippert/Heilshorn & Associates, +1-310-691-7100, dmarkley@lhai.com